ES2370136T3 - Sal de potasio de un inhibidor de la integrasa del vih. - Google Patents

Sal de potasio de un inhibidor de la integrasa del vih. Download PDF

Info

Publication number
ES2370136T3
ES2370136T3 ES05852866T ES05852866T ES2370136T3 ES 2370136 T3 ES2370136 T3 ES 2370136T3 ES 05852866 T ES05852866 T ES 05852866T ES 05852866 T ES05852866 T ES 05852866T ES 2370136 T3 ES2370136 T3 ES 2370136T3
Authority
ES
Spain
Prior art keywords
alkyl
compound
minutes
suspension
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05852866T
Other languages
English (en)
Spanish (es)
Inventor
Philip Pye
Remy Angelaud
Danny Mancheno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon Pharma UK Ltd
Istituto di Ricerche di Biologia Molecolare P Angeletti SpA
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme Ltd
Istituto di Ricerche di Biologia Molecolare P Angeletti SpA
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36171569&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2370136(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp and Dohme Ltd, Istituto di Ricerche di Biologia Molecolare P Angeletti SpA, Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme Ltd
Application granted granted Critical
Publication of ES2370136T3 publication Critical patent/ES2370136T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/557—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/02—Seven-membered rings
    • C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D313/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D313/12—[b,e]-condensed

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES05852866T 2004-12-03 2005-12-02 Sal de potasio de un inhibidor de la integrasa del vih. Expired - Lifetime ES2370136T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63313204P 2004-12-03 2004-12-03
US633132P 2004-12-03

Publications (1)

Publication Number Publication Date
ES2370136T3 true ES2370136T3 (es) 2011-12-13

Family

ID=36171569

Family Applications (2)

Application Number Title Priority Date Filing Date
ES05852866T Expired - Lifetime ES2370136T3 (es) 2004-12-03 2005-12-02 Sal de potasio de un inhibidor de la integrasa del vih.
ES05852840T Expired - Lifetime ES2375788T3 (es) 2004-12-03 2005-12-02 Sal de potasio de un inhibidor de integrasa de vih.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES05852840T Expired - Lifetime ES2375788T3 (es) 2004-12-03 2005-12-02 Sal de potasio de un inhibidor de integrasa de vih.

Country Status (35)

Country Link
US (2) US7754731B2 (enExample)
EP (2) EP1819683B1 (enExample)
JP (1) JP4705956B2 (enExample)
KR (2) KR20130122031A (enExample)
CN (1) CN101068793B (enExample)
AR (2) AR052034A1 (enExample)
AT (2) ATE518844T1 (enExample)
AU (1) AU2005311671B8 (enExample)
BR (1) BRPI0518760A8 (enExample)
CA (1) CA2588398C (enExample)
CR (1) CR9146A (enExample)
CY (1) CY1112859T1 (enExample)
DK (1) DK1819700T3 (enExample)
EA (1) EA012418B1 (enExample)
ES (2) ES2370136T3 (enExample)
GE (1) GEP20105086B (enExample)
HR (1) HRP20120066T1 (enExample)
IL (1) IL183614A (enExample)
MA (1) MA29120B1 (enExample)
ME (1) ME01985B (enExample)
MX (1) MX2007006639A (enExample)
MY (1) MY144320A (enExample)
NI (1) NI200700138A (enExample)
NO (1) NO338784B1 (enExample)
NZ (1) NZ555376A (enExample)
PE (1) PE20061148A1 (enExample)
PL (1) PL1819700T3 (enExample)
PT (1) PT1819700E (enExample)
RS (1) RS52197B (enExample)
SI (1) SI1819700T1 (enExample)
TN (1) TNSN07215A1 (enExample)
TW (1) TWI344463B (enExample)
UA (1) UA87884C2 (enExample)
WO (2) WO2006060730A2 (enExample)
ZA (1) ZA200704130B (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1725528T3 (da) 2004-03-11 2013-09-02 4Sc Ag Sulfonylpyrroler som hdac-inhibitorer
JP5228488B2 (ja) * 2004-12-03 2013-07-03 メルク・シャープ・アンド・ドーム・コーポレーション 放出速度調節組成物を含有しているカルボキサミドｈｉｖインテグラーゼ阻害薬の医薬配合物
MX2007006637A (es) * 2004-12-03 2007-06-19 Merck & Co Inc Uso de atazanavir para mejorar los parametros farmacocineticos de farmacos metabolizados por isoforma 1a1 de udp-glucuronosil- transferasa.
TR201907729T4 (tr) * 2004-12-03 2019-06-21 Merck Sharp & Dohme Bir anti-çekirdekleştirici ajan içeren farmasötik bileşim.
US20090087492A1 (en) * 2006-03-14 2009-04-02 Merck & Co., Inc. Processes and Apparatuses for the Production of Crystalline Organic Microparticle Compositions by Micro-Milling and Crystallization on Micro-Seed and Their Use
EP2046328A4 (en) 2006-07-19 2009-10-28 Univ Georgia Res Found PYRIDINONE DIKETOIC ACIDS: INHIBITORS OF HIV REPLICATION IN COMBINATION THERAPY
CA2702317A1 (en) * 2007-07-09 2009-01-15 Concert Pharmaceuticals, Inc. Novel pyrimidinecarboxamide derivatives
CA2710987A1 (en) * 2008-01-08 2009-07-16 Merck Sharp & Dohme Corp. Process for preparing n-substituted hydroxypyrimidinone carboxamides
ES2549387T3 (es) * 2009-06-02 2015-10-27 Hetero Research Foundation Procedimiento de preparación de raltegravir potásico amorfo
WO2011024192A2 (en) 2009-07-27 2011-03-03 Matrix Laboratories Ltd Novel polymorphs of raltegravir
ES2898348T3 (es) 2009-10-26 2022-03-07 Merck Sharp & Dohme Composiciones farmacéuticas sólidas que contienen un inhibidor de la integrasa
DE102009056636A1 (de) 2009-12-02 2011-06-09 Ratiopharm Gmbh Raltegravir-Polymorphe
MY172005A (en) 2009-12-07 2019-11-11 Univ Georgia Pyridinone hydroxycyclopentyl carboxamides : hiv integrase inhibators with therapeutic applications
ES2362598B1 (es) * 2009-12-17 2012-06-13 Consejo Superior De Investigaciones Científicas (Csic) Uso del raltegravir y derivados para la elaboración de medicamentos destinados al tratamiento de infecciones por herpesvirus.
CA2794952C (en) * 2010-04-01 2018-05-15 Critical Outcome Technologies Inc. Compounds and method for treatment of hiv
RU2012146517A (ru) 2010-04-01 2014-05-10 Тева Фармасьютикал Индастриз Лтд. Соли ральтегравира и их кристаллические формы
EP2575465A4 (en) * 2010-05-25 2013-11-20 Hetero Research Foundation Raltegravir SALTS
US9107922B2 (en) 2010-07-16 2015-08-18 Concert Pharmaceuticals, Inc. Pyrimidinecarboxamide derivatives
CN101914067B (zh) * 2010-08-26 2012-07-11 陈岱岭 N-甲基嘧啶酮的合成方法
JO3209B1 (ar) * 2010-11-05 2018-03-08 H Lundbeck As طريقة لتصنيع نالتريكسون
WO2012103105A1 (en) 2011-01-24 2012-08-02 Assia Chemical Industries Ltd. Processes for preparing raltegravir and intermediates in the processes
WO2012106534A2 (en) * 2011-02-02 2012-08-09 The Regents Of The University Of California Hiv integrase inhibitors
EP2694497A1 (en) 2011-04-06 2014-02-12 Lupin Limited Novel salts of raltegravir
CA2833006A1 (en) * 2011-04-22 2012-10-26 Merck Sharp & Dohme Corp. Taste-masked formulations of raltegravir
US9968607B2 (en) 2011-04-25 2018-05-15 Hetero Research Foundation Pharmaceutical compositions of raltegravir, methods of preparation and methods of use therof
EP2522665A1 (en) 2011-05-03 2012-11-14 Sandoz Ag Crystalline sodium salt of an HIV integrase inhibitor
ES2450944T3 (es) 2011-06-01 2014-03-25 Ratiopharm Gmbh Composición y comprimido que comprenden raltegravir
EP2755968A1 (de) 2011-09-16 2014-07-23 Hexal AG Neue polymorphe form von raltegravir-kalium
CN103130788B (zh) * 2011-11-24 2015-09-02 南开大学 嘧啶酰胺类化合物及其制备方法、抗hiv活性和抗tmv活性
CN103130787B (zh) * 2011-11-24 2015-06-10 南开大学 嘧啶酮酰胺类化合物及其制备方法、抗hiv活性和抗tmv活性
EP2804607B1 (en) 2011-12-26 2020-09-16 Emcure Pharmaceuticals Limited Synthesis of raltegravir
US20150328215A1 (en) 2012-01-25 2015-11-19 Lupin Limited Stable amorphous raltegravir potassium premix and process for the preparation thereof
WO2014064711A2 (en) * 2012-10-22 2014-05-01 Hetero Research Foundation Methods of administering raltegravir and raltegravir compositions
EP2818470A1 (en) 2013-06-27 2014-12-31 Basf Se Cocrystals of raltegravir potassium
EP3022209B1 (en) 2013-07-17 2018-03-07 ratiopharm GmbH Dolutegravir potassium salt
WO2015114608A1 (en) 2014-02-03 2015-08-06 Mylan Laboratories Ltd Processes for the preparation of intermediates of raltegravir
EP3119773A1 (en) * 2014-03-21 2017-01-25 Mylan Laboratories Ltd. A premix of crystalline raltegravir potassium salt and a process for the preparation thereof
US10257840B2 (en) 2014-10-22 2019-04-09 Telefonaktiebolaget Lm Ericsson (Publ) Operation of wireless local area network in the presence of periodic interference
WO2016075605A1 (en) 2014-11-10 2016-05-19 Aurobindo Pharma Ltd An improved process for the preparation of raltegravir
EP3472134B1 (en) * 2016-06-21 2021-10-20 Pharmathen S.A. Process for preparing compounds useful as intermediates for the preparation of raltegravir
JP2019529410A (ja) * 2016-09-15 2019-10-17 ルピン・リミテッド 純粋で安定な結晶のラルテグラビルカリウム３型の製造方法
CN108610338A (zh) * 2016-12-12 2018-10-02 天津国际生物医药联合研究院 一种嘧啶酮酰胺类化合物的制备方法
ES2909302T3 (es) 2017-11-14 2022-05-06 Cambrex Profarmaco Milano S R L Proceso para la preparación de Raltegravir
WO2019236395A1 (en) * 2018-06-06 2019-12-12 Merck Sharp & Dohme Corp. Formulations of raltegravir
GB201907305D0 (en) * 2019-05-23 2019-07-10 Douglas Pharmaceuticals Ltd Treatment of conditions
US12465565B2 (en) 2020-01-23 2025-11-11 Lupin Limited Pharmaceutical compositions of raltegravir

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH624391A5 (enExample) * 1976-12-14 1981-07-31 Ciba Geigy Ag
US5413999A (en) * 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US5717097A (en) * 1991-11-08 1998-02-10 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
IL121789A (en) * 1996-10-03 2001-06-14 Rohm & Haas A medicinal product for inhibiting mammalian cell tumors
PL348596A1 (en) * 1998-12-25 2002-06-03 Shionogi & Co Aromatic heterocycle compounds having hiv integrase inhibiting activities
IT1318424B1 (it) * 2000-03-24 2003-08-25 Unihart Corp Composti con attivita' anti-hiv.
ATE430745T1 (de) 2000-10-12 2009-05-15 Merck & Co Inc Aza- und polyaza naphthalenyl karboxamide als inhibitoren der hiv-integrase
GB0028483D0 (en) * 2000-11-22 2001-01-10 Hoffmann La Roche Hydroxyethylamine HIV protease inhibitors
DE60209381T2 (de) * 2001-10-26 2006-10-05 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. N-substituierte hydroxypyrimidinoncarboxamid-hemmer der hiv-integrase
US7354932B2 (en) * 2001-12-21 2008-04-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
CN1596255A (zh) * 2001-12-21 2005-03-16 阿诺麦德股份有限公司 具有强效的与趋化因子受体结合的杂环化合物
WO2004046115A1 (ja) * 2002-11-20 2004-06-03 Japan Tobacco Inc. ４−オキソキノリン化合物及びそのｈｉｖインテグラーゼ阻害剤としての利用
BR0317749A (pt) * 2002-12-27 2005-11-22 Angeletti P Ist Richerche Bio Composto, composição farmacêutica, e, uso de um composto
TW200423930A (en) * 2003-02-18 2004-11-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitors
JP5228488B2 (ja) * 2004-12-03 2013-07-03 メルク・シャープ・アンド・ドーム・コーポレーション 放出速度調節組成物を含有しているカルボキサミドｈｉｖインテグラーゼ阻害薬の医薬配合物
MX2007006637A (es) 2004-12-03 2007-06-19 Merck & Co Inc Uso de atazanavir para mejorar los parametros farmacocineticos de farmacos metabolizados por isoforma 1a1 de udp-glucuronosil- transferasa.
TR201907729T4 (tr) 2004-12-03 2019-06-21 Merck Sharp & Dohme Bir anti-çekirdekleştirici ajan içeren farmasötik bileşim.

Also Published As

Publication number Publication date
AU2005311671B2 (en) 2011-01-27
MA29120B1 (fr) 2007-12-03
NO20073404L (no) 2007-07-02
ZA200704130B (en) 2008-08-27
KR20130122031A (ko) 2013-11-06
ATE518844T1 (de) 2011-08-15
CA2588398C (en) 2011-07-12
TW200631944A (en) 2006-09-16
AR052034A1 (es) 2007-02-28
WO2006060712A9 (en) 2006-07-27
NZ555376A (en) 2009-11-27
AU2005311671B8 (en) 2011-02-10
CR9146A (es) 2007-10-04
NI200700138A (es) 2008-05-13
PT1819700E (pt) 2012-02-01
US20060122205A1 (en) 2006-06-08
IL183614A0 (en) 2007-09-20
NO338784B1 (no) 2016-10-17
AR101429A2 (es) 2016-12-21
JP2008521933A (ja) 2008-06-26
ME01985B (me) 2012-10-31
KR20070089990A (ko) 2007-09-04
EP1819683A2 (en) 2007-08-22
ATE534645T1 (de) 2011-12-15
MX2007006639A (es) 2007-06-19
MY144320A (en) 2011-08-29
PE20061148A1 (es) 2006-11-09
KR101350420B1 (ko) 2014-02-17
WO2006060712A3 (en) 2006-09-21
BRPI0518760A2 (pt) 2008-12-09
US7754731B2 (en) 2010-07-13
EA012418B1 (ru) 2009-10-30
TWI344463B (en) 2011-07-01
BRPI0518760A8 (pt) 2017-12-12
HRP20120066T1 (hr) 2012-03-31
ES2375788T3 (es) 2012-03-06
US8357798B2 (en) 2013-01-22
CN101068793A (zh) 2007-11-07
JP4705956B2 (ja) 2011-06-22
EA200701204A1 (ru) 2007-12-28
PL1819700T3 (pl) 2012-04-30
HK1115011A1 (en) 2008-11-14
WO2006060730A3 (en) 2006-08-17
SI1819700T1 (sl) 2012-07-31
DK1819700T3 (da) 2012-03-19
CN101068793B (zh) 2011-05-25
US20100249410A1 (en) 2010-09-30
WO2006060712A2 (en) 2006-06-08
CA2588398A1 (en) 2006-06-08
GEP20105086B (en) 2010-10-11
TNSN07215A1 (en) 2008-11-21
IL183614A (en) 2012-03-29
RS52197B (sr) 2012-10-31
AU2005311671A1 (en) 2006-06-08
WO2006060730A2 (en) 2006-06-08
UA87884C2 (uk) 2009-08-25
EP1819700A2 (en) 2007-08-22
EP1819700B1 (en) 2011-11-23
EP1819683B1 (en) 2011-08-03
CY1112859T1 (el) 2016-04-13

Similar Documents

Publication Publication Date Title
EP1819683B1 (en) Potassium salt of an hiv integrase inhibitor
ES2291642T3 (es) Hidroxinaftiridinoncarboxamidas utiles como inhibidores de la integrasa de vih.
ES2282691T3 (es) Preparacion de ih-imidazo(4,5-c)quinolin-4-amina mediante nuevos int ermedios 1h-imidazo (4,5-c)quinolin-4-ciano y 1h-imidazo (4,5-c).
ES2590508T3 (es) Purinas macrocíclicas para el tratamiento de infecciones víricas
JP4743659B2 (ja) 新規フェニルアラニン誘導体
ES2230841T3 (es) Pirazolinas y triazolinas disustituidas como inhibidores del factor xa.
IL264402A (en) Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
CN1930127B (zh) 用于合成cxcr4拮抗剂的方法
US9120818B2 (en) Process and intermediates for preparing macrolactams
KR20050087865A (ko) ＨＩＶ 인테그라제 억제제로서 유용한테트라하이드로-4Ｈ-피리도[1,2-ａ]피리미딘 및 관련화합물
ZA200505040B (en) Process for the production of 3'-nucleoside prodrus
WO2004072030A2 (en) Process for preparing pyrrolotriazine kinase inhibitors
JP6568221B2 (ja) ベンゾオキサゾールオキサジンケトン系化合物の製造方法及びその中間体と結晶形
SK9442001A3 (en) Imidazo[4,5-c]-pyridine-4-on-derivatives, process for the preparation thereof, use thereof and pharmaceutical composition comprising same
CN103130787B (zh) 嘧啶酮酰胺类化合物及其制备方法、抗hiv活性和抗tmv活性
CN105283458B (zh) 制备4-((1r,2s,5r)-6-(苄氧基)-7-氧代-1,6-二氮杂双环[3.2.1]辛烷-2-甲酰胺基)哌啶-1-甲酸叔丁基酯
ES2489815A1 (es) Nuevos p-terfenilos hexakis-sustituidos con grupos bilaterales para el tratamiento de la infección por el virus de la inmunodeficiencia humana tipo 1 (VIH-1) y otras enfermedades
JP2894576B2 (ja) 新生物の治療のためのフォ−レ−ト及びアンチフォ−レ−トとのジフルオログルタミン酸のコンジュゲ−ト類
AU2021357176A1 (en) Substituted tricyclic compounds
DK164855B (da) Spergualin-beslaegtede forbindelser med en phenylengruppe, fremgangsmaade til fremstilling deraf samt en farmaceutisk sammensaetning
ES2357768T3 (es) Ácidos 2-(3-fenil-2-piperazinil-2,4-dihidroquinazolin-4-il)-acéticos como agentes antivirales, especialmente contra citomegalovirus.
ES2553834T3 (es) Un nuevo método para producir agentes antifolatos que tienen ácido glutámico como parte de su estructura
ES2370986A1 (es) Nuevos inhibidores de cxcr4 como agentes anti-vih.
CN116284046B (zh) 巴洛沙韦衍生物及其制备方法和应用
BRPI0509667B1 (pt) composto, processo para a preparação de um composto de fórmula (i), medicamento e uso de um composto